MEDI-1912 is a human monoclonal antibody targeting NGF/bNGF. It inhibits signaling via the TrkA and p75 receptors and can be utilized in chronic pain research.
Target:
Trk receptor|||Neurokinin receptor
* VAT and and shipping costs not included. Errors and price changes excepted
